SLNO Stock Summary and Trading Ideas (Soleno Therapeutics | NASDAQ:SLNO)

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Soleno Therapeutics trades on the NASDAQ stock market under the symbol SLNO.

As of March 4, 2026, SLNO stock price climbed to $38.13 with 1,074,292 million shares trading.

SLNO has a beta of 0.19, meaning it tends to be less sensitive to market movements. SLNO has a correlation of 0.00 to the broad based SPY ETF.

SLNO has a market cap of $2.05 billion. This is considered a Mid Cap stock.

Last quarter Soleno Therapeutics reported $92 million in Revenue and $.80 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.12.

In the last 3 years, SLNO traded as high as $90.32 and as low as $1.94.

The top ETF exchange traded funds that SLNO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

SLNO has underperformed the market in the last year with a price return of -14.2% while the SPY ETF gained +20.0%. SLNO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.6% and -1.2%, respectively, while the SPY returned +0.4% and -0.2%, respectively.

SLNO support price is $36.26 and resistance is $39.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLNO shares will trade within this expected range on the day.